Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free…
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the…